Home Cart Sign in  
Chemical Structure| 114482-86-9 Chemical Structure| 114482-86-9

Structure of Oroxin B
CAS No.: 114482-86-9

Chemical Structure| 114482-86-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Oroxin B, a natural product isolated and purified from the roots of Scutellaria baicalensis., can selectively induce tumor-suppressive ER stress and concurrently inhibit tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy.

Synonyms: Hypocretin-2

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Oroxin B

CAS No. :114482-86-9
Formula : C27H30O15
M.W : 594.52
SMILES Code : O=C1C=C(C2=CC=CC=C2)OC3=C1C(O)=C(O)C(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]5[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O5)O4)=C3
Synonyms :
Hypocretin-2
MDL No. :MFCD22125002

Safety of Oroxin B

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312-P330-P501

Related Pathways of Oroxin B

PI3K-AKT

Isoform Comparison

Biological Activity

Target
  • PI3K

In Vitro:

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMM) 50μM 1-3 days or 3-5 days Investigate the time-dependent effect of OB on RANKL-induced osteoclast formation, results showed that early addition of OB significantly reduced osteoclast formation PMC8643139
Bone marrow-derived macrophages (BMM) 10μM, 20μM, 30μM, 40μM, 50μM 1, 3, 5, 7 days Evaluate the cytotoxic effects of OB on BMMs, results showed that OB concentration up to 50μM had no negative effect on BMMs proliferation PMC8643139
HepG2 cells 0.2, 0.4, 0.6 mg/mL 24 hours To evaluate the effect of Oroxin B on the proliferation of HepG2 cells, the results showed that the apoptosis and necrosis rates of cells in the OB-treated groups were significantly higher than those in the control group. PMC6930563
Primary mice chondrocytes 160 µM 24 hours OB reversed the expression level of anabolic-related proteins (Aggrecan and Collagen II) in IL-1β-induced chondrocytes. PMC9751055
Human hepatoma cell line SMMC-7721 0.34, 1.01, 1.68 µM 48 hours OB inhibited the proliferation of SMMC-7721 cells in a dose-dependent manner and induced apoptosis. PMC5909317
HepG2 cells 200 mg/ml 12 h To evaluate the role of SR-A3 in fatty liver disease, results showed a significant reduction in Sr-a3 mRNA expression in HepG2 cells treated with OA and PA PMC11897346

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Hamsters HFHCD-induced MAFLD model Oral gavage 30 mg/kg Daily for 4 weeks To evaluate the therapeutic effect of PTEN agonist Oroxin B on fatty liver, results showed Oroxin B partially reversed the metabolic abnormalities caused by SR-A3 deficiency PMC11897346
C57BL/6 mice Ovariectomized model Intraperitoneal injection 40 mg/kg Every 2 days for 6 weeks Verify the protective effect of OB on ovariectomy-induced bone loss, results showed that OB treatment significantly reduced bone loss and osteoclast number PMC8643139
SD rats DEN-induced liver cancer model Oral 4, 12, 24 mg/kg body weight/day Once daily for 16 weeks To evaluate the anti-tumor effect of Oroxin B on the DEN-induced liver cancer model, the results showed that OB significantly reduced the number of liver nodules, improved liver histopathological structure, and decreased the levels of AFP and ALT in serum. PMC6930563
C57BL/6 male mice Destabilized medial meniscus (DMM)-induced osteoarthritis model Intra-articular injection 160 mM Twice a week for 8 weeks OB attenuated the cartilage degradation, as well as reversed the expression level of anabolic and catabolic-related proteins such as Aggrecan, Collagen II, and MMP13 induced in DMM-induced OA models. PMC9751055
Sprague-Dawley (SD) rats Rat metabolic study model Oral 1.24 mg/mL,15 mL/kg Single dose Study the pharmacokinetics and metabolites of Oroxin B in rats PMC11254595

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.68mL

0.34mL

0.17mL

8.41mL

1.68mL

0.84mL

16.82mL

3.36mL

1.68mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories